As Many as 86% of Patients With Ocular Discomfort Have Meibomian Gland Dysfunction (MGD).1
If you have your password, Click “Continue” below to view webinars, hosted by TearScience, where you will learn more about the pathophysiology of MGD and the latest in effective treatment options.
Participants will also discover how the LipiFlow Thermal Pulsation system provides clinical improvement in overall dry eye symptoms for 79% of patients at 4 weeks following a single treatment.2
The webinar will include LipiFlow product and safety information.
Recently FDA-cleared to treat Meibomian Gland Dysfunction (MGD) and evaporative dry eye. The second generation of LipiFlow received U.S. Food and Drug Administration (FDA) clearance on December 23, 2011.
Please complete this form to receive your password to watch the latest webcast from TearScience.
1 Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous deficient and evaporative dry eye in a clinic-based patient population. Cornea. In press.
2TearScience Clinical Trial LF-001.